Clinical Trial

Two Dose Levels of Privigen in Pediatric CIDP

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
Protocol Amendment History 36 amendments
This ClinicalTrials.gov record has been amended 36 times since 2018-09-24; most recent amendment 2026-05-28.
Status change: Active, Not Recruiting → Recruiting 2020-07-14
Status change: Recruiting → Active, Not Recruiting 2020-04-02
Status change: Not Yet Recruiting → Recruiting 2019-05-07
Trial Details
NCT Number NCT03684018
Lead Sponsor CSL Behring
Conditions Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Enrollment 30 participants
Start Date 2019-02-28
Primary Completion 2029-12-20 (estimated)
Study Completion 2029-12-20 (estimated)
Updated on ClinicalTrials.gov 2026-06-01